Medications in Patients with Dementia and Behavioral Disturbance.

Autor:	Zhong W; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA., Liu X; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA., Voss T; Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA., Khalilieh S; Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA., Khandker RK; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA., Bortnichak E; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA., Liaw KL; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Jazyk:	angličtina
Zdroj:	Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2021 Jun 17; Vol. 5 (1), pp. 535-540. Date of Electronic Publication: 2021 Jun 17 (Print Publication: 2021).
DOI:	10.3233/ADR-210023
Abstrakt:	Background: Behavioral disturbance (BD) is common in dementia patients, with no FDA approved medications for this condition. Little data exists on the real-world medication use in this population. Objective: To describe real-world medications use in this population. Methods: A cross-sectional study was conducted using the MarketScan database for outpatient medications and the Cerner database for inpatient medications. The study period was Oct 2015-Jun 2018. Patients with dementia and BD were identified through ICD-10-CM. We examined outpatient medications prescribed during 6-month before or after BD event date, and inpatient medications during inpatient visits, especially on central nervous systems (CNS) drugs including antidementia drugs, antidepressants, antipsychotics, anxiolytics, and anticonvulsants. Results: A total of 56,544 outpatients and 34,245 patient hospitalizations were assessed separately. Among outpatients, patients filled more medications after a BD event. The use of the five CNS drug classes generally increased after a BD event, and the largest increase was seen in antipsychotics (23%to 33%). Among inpatients, the median number of medications used in each hospitalization was 14. The use of antipsychotics was particularly high (64%), followed by anxiolytics (51%). A list of 60 unique medications were suggested to be the commonly used drugs in dementia patients with BD. Conclusion: In dementia patients with BD, anti-dementia medications, antidepressants, anticonvulsants, hypnotics and antipsychotics were the most used drug classes. Antidepressants and antipsychotics use were more frequent after a BD event, which suggests a need for safe drugs targeting BD in dementia patients. Competing Interests: All the authors are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, all of whom may own stock and/or hold stock options in the Company. (© 2021 – The authors. Published by IOS Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu